UK plays catch-up in medicinal cannabis market
1 November 2018 marks a turning point in relation to the use of medicinal cannabis in the UK. The Misuse of Drugs (Amendments) (Cannabis...
Life Sciences
About Me
Senior associate in DLA Piper's corporate team and a member of the firm's Life Science sector. I am also an honorary lecturer at the University of Birmingham. Specialising in capital markets advising on IPOs (both on the London Stock Exchange's Main Market and AIM), secondary offerings, takeovers and mergers and public company corporate governance. I am also active in M&A transactions acting for both private and public companies with a particular focus on cross-border transactions.
Robert Newman's Passles
Most Read
Most Shared
The Biomedical Bubble debate
The FT commented earlier today on the highly provocative report "The Biomedical Bubble" published by Nesta, the charity which, in its own...
Was the acquisition of PillPack inevitable and a sign of what is to come?
Two weeks after a certain tech giant announced its reported $1 billion acquisition of PillPack, I consider whether this move by the...
Government must do more to implement the Life Sciences Industrial Strategy
If anyone wondered why have a two-house system of parliament, perhaps a good starting point would be to read the opinion of the Science...
Reflecting on the Med-Tech Innovation Expo 2018
Being 'sent to Coventry' is not ordinarily something one wants to hear, but at the end of April for the last few years I have made my...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net